Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Cytogen halts autologous lymphocyte therapy program

March 27, 1998

Coulter completes patient enrollment in Bexxar phase III trial

March 25, 1998

Phase II ImmTher trial begins in pediatric cancer patients

March 19, 1998

Cel-Sci expands North American clinical trial for Multikine

March 18, 1998

Ribi ImmunoChem and Schering-Plough sign distribution agreement for Melacine

March 18, 1998

Techniclone to begin TNT clinical trials using unique delivery system

March 16, 1998

Genentech and DAKO establish development agreement for HER2 detection

March 13, 1998

Patient enrollment completed for phase I/II pancreatic cancer trial

March 13, 1998

Avicidin advances to phase II

March 5, 1998

DiagnoCure signs agreements related to development of targeted nanoerythrosomes

March 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...